Bio-Rad Laboratories, Inc. (BIO.B) stock
BIO.BNYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 8/3055% above fair value
$379.50+0.00 (0.00%)
Close on Oct 29, 2026Market cap $10.18BP/E 46.2Yield –
Bio-Rad Laboratories gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Bio-Rad Laboratories's gross profit for the twelve months ending Jun 30, 2026 was $1.34B, down 0.4% year over year. For fiscal 2025 it was $1.34B, down 2.8% from the year before. Over ten years it grew 1.8% a year on average. The highest annual figure on record is $1.64B in fiscal 2021.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.34B | -2.8% |
| FY2024 | Dec 31, 2024 | $1.38B | -3.4% |
| FY2023 | Dec 31, 2023 | $1.43B | -9.0% |
| FY2022 | Dec 31, 2022 | $1.57B | -4.3% |
| FY2021 | Dec 31, 2021 | $1.64B | +13.9% |
| FY2020 | Dec 31, 2020 | $1.44B | +14.4% |
| FY2019 | Dec 31, 2019 | $1.26B | +2.8% |
| FY2018 | Dec 31, 2018 | $1.22B | +3.0% |
| FY2017 | Dec 31, 2017 | $1.19B | +4.3% |
| FY2016 | Dec 31, 2016 | $1.14B | +1.5% |
| FY2015 | Dec 31, 2015 | $1.12B | -4.8% |
| FY2014 | Dec 31, 2014 | $1.18B | +0.0% |
| FY2013 | Dec 31, 2013 | $1.18B | +2.0% |
| FY2012 | Dec 31, 2012 | $1.16B | -2.0% |
| FY2011 | Dec 31, 2011 | $1.18B | +8.0% |
| FY2010 | Dec 31, 2010 | $1.09B | +9.2% |
| FY2009 | Dec 31, 2009 | $999.84M | +3.9% |
| FY2008 | Dec 31, 2008 | $962.52M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $345.80M | +0.1% |
| Q1 FY2026 | Mar 31, 2026 | $309.40M | +1.1% |
| Q4 FY2025 | Dec 31, 2025 | $345.20M | +0.9% |
| Q3 FY2025 | Sep 30, 2025 | $343.40M | -3.5% |
| Q2 FY2025 | Jun 30, 2025 | $345.30M | -2.8% |
| Q1 FY2025 | Mar 31, 2025 | $306.00M | -6.1% |
| Q4 FY2024 | Dec 31, 2024 | $342.00M | -6.6% |
| Q3 FY2024 | Sep 30, 2024 | $355.90M | +6.0% |
| Q2 FY2024 | Jun 30, 2024 | $355.10M | -2.0% |
| Q1 FY2024 | Mar 31, 2024 | $325.90M | -10.1% |
| Q4 FY2023 | Dec 31, 2023 | $366.30M | -7.8% |
| Q3 FY2023 | Sep 30, 2023 | $335.70M | -9.9% |
| Q2 FY2023 | Jun 30, 2023 | $362.50M | -8.2% |
| Q1 FY2023 | Mar 31, 2023 | $362.40M | -10.0% |
| Q4 FY2022 | Dec 31, 2022 | $397.10M | -0.7% |
| Q3 FY2022 | Sep 30, 2022 | $372.60M | -14.6% |
| Q2 FY2022 | Jun 30, 2022 | $395.00M | -1.5% |
| Q1 FY2022 | Mar 31, 2022 | $402.60M | +0.5% |
| Q4 FY2021 | Dec 31, 2021 | $399.90M | -13.1% |
| Q3 FY2021 | Sep 30, 2021 | $436.50M | +18.8% |
| Q2 FY2021 | Jun 30, 2021 | $401.10M | +36.9% |
| Q1 FY2021 | Mar 31, 2021 | $400.50M | +26.2% |
| Q4 FY2020 | Dec 31, 2020 | $460.10M | +39.3% |
| Q3 FY2020 | Sep 30, 2020 | $367.30M | +19.6% |
| Q2 FY2020 | Jun 30, 2020 | $293.00M | -4.8% |
| Q1 FY2020 | Mar 31, 2020 | $317.40M | +1.8% |
| Q4 FY2019 | Dec 31, 2019 | $330.40M | -0.7% |
| Q3 FY2019 | Sep 30, 2019 | $307.00M | +7.1% |
| Q2 FY2019 | Jun 30, 2019 | $307.80M | +2.0% |
| Q1 FY2019 | Mar 31, 2019 | $311.80M | +3.2% |
| Q4 FY2018 | Dec 31, 2018 | $332.60M | -3.7% |
| Q3 FY2018 | Sep 30, 2018 | $286.70M | -4.1% |
| Q2 FY2018 | Jun 30, 2018 | $301.70M | +10.4% |
| Q1 FY2018 | Mar 31, 2018 | $302.20M | +11.9% |
| Q4 FY2017 | Dec 31, 2017 | $345.20M | +9.8% |
| Q3 FY2017 | Sep 30, 2017 | $299.00M | +7.0% |
| Q2 FY2017 | Jun 30, 2017 | $273.40M | – |
| Q1 FY2017 | Mar 31, 2017 | $270.10M | – |
| Q4 FY2016 | Dec 31, 2016 | $314.40M | – |
| Q3 FY2016 | Sep 30, 2016 | $279.50M | – |